Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06041087
Other study ID # 2019-045b
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2023
Est. completion date September 1, 2025

Study information

Verified date December 2023
Source York University
Contact Andrea R Josse, PhD
Phone 1-416-736-2100
Email ajosse@yorku.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates whether dairy products will positively impact loading exercise-induced bone turnover and bone cell activity and/or the post-exercise inflammatory response in healthy young adults compared to a carbohydrate drink and/or water.


Description:

Introduction: Two million individuals at a cost of around 4.6 billion dollars a year in Canada suffer from osteoporosis. It is important to investigate strategies that can reduce bone loss and/or increase bone mass. Similarly, inflammation is associated with many different disease states, and investigating strategies to reduce systemic inflammation is prudent. Nutrition and exercise may be inexpensive and accessible strategies to improve bone health and inflammation and should be explored in different contexts and implemented. Our proposed research combines both nutrition and exercise along with the assessment of bone turnover and inflammatory markers in healthy young adults. Design: Randomized controlled crossover trial Participants: Healthy, university aged males and females. Methods: During the study participants will complete 4 different acute exercise and nutritional supplement trials, in random order. The four trials are: 1) exercise+carbohydrate (CHO), 2) exercise+milk (Milk), 3) exercise+Greek yogurt (GY), and 4) exercise+water (W). The whole study will take a maximum of 16 weeks and each supplement trial will be separated by 2-4 weeks. Outcomes: several markers of bone turnover and bone cell activity as well as markers of inflammation will be measured in the blood, before exercise and at different times post-exercise and post supplement consumption.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date September 1, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Between the ages of 18-30 years - Normal BMI (18.5-24.9) kg/m^2 - Low to moderately physically active (0-2 times/week) - No allergy to dairy protein or lactose intolerance - On no medication related to a chronic condition - On birth control or naturally cycling with a regular menstrual cycle) Exclusion Criteria: - Regular smoker (cigarettes, e-cigarettes (e.g., vapes) or cannabis) - Any chronic condition, inflammatory, or auto-immune condition

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High-Intensity Exercise
A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
Dietary Supplement:
Carbohydrate (Maltodextrin powder mixed with water)
50g consumed immediately after exercise and 1h after exercise.
Skim Milk
500ml consumed immediately after exercise and 1h after exercise.
Greek yogurt
200g consumed immediately after exercise and 1h after exercise.
Water
500ml consumed immediately after exercise and 1h after exercise.

Locations

Country Name City State
Canada York University Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
York University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute Bone Turnover/Cell Activity OPG measured in serum/plasma Pre-exercise
Primary Acute Bone Turnover/Cell Activity RANKL measured in serum/plasma Pre-exercise
Primary Acute Bone Turnover/Cell Activity OC measured in serum/plasma Pre-exercise
Primary Acute Bone Turnover/Cell Activity SOST measured in serum/plasma Pre-exercise
Primary Acute Bone Turnover/Cell Activity CTX measured in serum/plasma Pre-exercise
Primary Acute Bone Turnover/Cell Activity OPG measured in serum/plasma 5 minutes post-exercise
Primary Acute Bone Turnover/Cell Activity RANKL measured in serum/plasma 5 minutes post-exercise
Primary Acute Bone Turnover/Cell Activity OC measured in serum/plasma 5 minutes post-exercise
Primary Acute Bone Turnover/Cell Activity SOST measured in serum/plasma 5 minutes post-exercise
Primary Acute Bone Turnover/Cell Activity CTX measured in serum/plasma 5 minutes post-exercise
Primary Acute Bone Turnover/Cell Activity OPG measured in serum/plasma 1 hour post-exercise
Primary Acute Bone Turnover/Cell Activity RANKL measured in serum/plasma 1 hour post-exercise
Primary Acute Bone Turnover/Cell Activity OC measured in serum/plasma 1 hour post-exercise
Primary Acute Bone Turnover/Cell Activity SOST measured in serum/plasma 1 hour post-exercise
Primary Acute Bone Turnover/Cell Activity CTX measured in serum/plasma 1 hour post-exercise
Primary Acute Bone Turnover/Cell Activity OPG measured in serum/plasma 4 hours post-exercise
Primary Acute Bone Turnover/Cell Activity RANKL measured in serum/plasma 4 hours post-exercise
Primary Acute Bone Turnover/Cell Activity OC measured in serum/plasma 4 hours post-exercise
Primary Acute Bone Turnover/Cell Activity SOST measured in serum/plasma 4 hours post-exercise
Primary Acute Bone Turnover/Cell Activity CTX measured in serum/plasma 4 hours post-exercise
Primary Acute Bone Turnover/Cell Activity OPG measured in serum/plasma 24 hours post-exercise
Primary Acute Bone Turnover/Cell Activity RANKL measured in serum/plasma 24 hours post-exercise
Primary Acute Bone Turnover/Cell Activity OC measured in serum/plasma 24 hours post-exercise
Primary Acute Bone Turnover/Cell Activity SOST measured in serum/plasma 24 hours post-exercise
Primary Acute Bone Turnover/Cell Activity CTX measured in serum/plasma 24 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines TNF-alpha measured in serum/plasma. Pre-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-6 measured in serum/plasma. Pre-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-1B measured in serum/plasma. Pre-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-10 measured in serum/plasma. Pre-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines TNF-alpha measured in serum/plasma. 5 minutes post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-6 measured in serum/plasma. 5 minutes post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-1B measured in serum/plasma. 5 minutes post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-10 measured in serum/plasma. 5 minutes post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines TNF-alpha measured in serum/plasma. 1 hour post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-6 measured in serum/plasma. 1 hour post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-1B measured in serum/plasma. 1 hour post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-10 measured in serum/plasma. 1 hour post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines TNF-alpha measured in serum/plasma. 4 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-6 measured in serum/plasma. 4 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-1B measured in serum/plasma. 4 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-10 measured in serum/plasma. 4 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines TNF-alpha measured in serum/plasma. 24 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-6 measured in serum/plasma. 24 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-1B measured in serum/plasma. 24 hours post-exercise
Primary Systemic Inflammation - Serum/Plasma Cytokines IL-10 measured in serum/plasma. 24 hours post-exercise
Primary Systemic inflammation - Immune Cells Leukocytes measured via flow cytometry Pre-exercise
Primary Systemic inflammation - Immune Cells Leukocytes measured via flow cytometry 1 hour post-exercise
Primary Systemic inflammation - Immune Cells Leukocytes measured via flow cytometry 4 hours post-exercise
Primary Systemic inflammation - Immune Cells Leukocytes measured via flow cytometry 24 hours post-exercise
Secondary Muscle soreness Muscle soreness rated on a 0-5 scale. Pre-exercise
Secondary Muscle soreness Muscle soreness rated on a 0-5 scale. 5 minutes post-exercise
Secondary Muscle soreness Muscle soreness rated on a 0-5 scale. 4 hours post-exercise
Secondary Muscle soreness Muscle soreness rated on a 0-5 scale. 24 hours post-exercise
Secondary Performance - Jump Height Vertical jump height measured using a counter movement jump technique. Pre-exercise
Secondary Performance - Jump Height Vertical jump height measured using a counter movement jump technique. 5 minutes post-exercise
Secondary Performance - Jump Height Vertical jump height measured using a counter movement jump technique. 4 hours post-exercise
Secondary Performance - Jump Height Vertical jump height measured using a counter movement jump technique. 24 hours post-exercise
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1